UroGen Pharma (Nasdaq:URGN) announced that it entered into a securities purchase agreement worth approximately $120 million. The placement includes the issuance of nearly 12.6 million ordinary shares or pre-funded warrants priced at $9.54 per share. UroGen expects the placement to close on or about today, subject to customary closing conditions. RA Capital Management and Great […]
Hydrogels
Early study supports experimental hydrogel injection for chronic low back pain
A study demonstrated that an experimental hydrogel formulation was safe and effective in substantially relieving chronic low back pain. Research presented at the Society of Interventional Radiology Annual Scientific Meeting in Boston supported the hydrogel, which was injected into spinal discs in an effort to relieve chronic low back pain caused by degenerative disc disease […]
Boston Scientific warns on some SpaceOAR systems
Boston Scientific (NYSE:BSX) has issued an urgent field safety notice in Europe due to potential issues with its SpaceOAR systems. Marlborough, Massachusetts-based Boston Scientific’s SpaceOAR system is an absorbable polyethylene glycol hydrogel spacer for separating the prostate from the rectal wall during radiation treatment for prostate cancer. The SpaceOAR Vue, the next-generation hydrogel spacer, offers enhanced […]
First patients enrolled in trial for Boston Scientific’s SpaceOAR Vue hydrogel
GenesisCare announced today that it enrolled the first patients in a trial for Boston Scientific’s (NYSE:BSX) SpaceOAR Vue hydrogel. Boston Scientific’s SpaceOAR Vue hydrogel will be evaluated in the SABRE trial, sponsored by Boston Scientific, for prostate cancer patients receiving stereotactic body radiation therapy (SBRT). Get the full story at our sister site, MassDevice.
Catalent beats The Street in Q1, raises revenue guidance
Catalent (NYSE:CTLT) shares dipped today despite first-quarter financial results that beat the consensus forecast. The Somerset, New Jersey-based company posted profits of $93 million, or 49¢ per share, on sales of $1.025 billion for the three months ended Sept. 30, 2021, for a 13.4% bottom-line gain on sales growth of 21.2%. Get the full story at […]
Drug delivery tech developer Virpax Pharmaceuticals prices $40M offering
Virpax Pharmaceuticals (NSDQ:VRPX) announced today that it priced an underwritten public offering worth approximately $40 million. Berwyn, Pennsylvania-based Virpax’s offering includes 6.67 million shares of common stock priced at $6 per share, totaling just over $40 million before deducting underwriting discounts and offering expenses. Additionally, the company granted underwriters a 45-day option to purchase up […]
Gelteq wins U.S. patent for gel-based blood glucose testing platform
Gelteq announced today that it received a U.S. patent for its GTT Gel product for testing human response to oral glucose loads. Melbourne, Australia-based Gelteq designed its GTT Gel diabetes diagnostic system for use in pathology labs and at-home testing through a proprietary gel-based delivery system. The tests take blood samples from patients at different […]
Researchers reverse diabetes in mice using nanoscale device
Scientists at Washington University (St. Louis) and Cornell University (Ithaca, N.Y.) successfully implanted insulin-secreting cells in mice with type 1 diabetes. The cells proved capable of reversing chemically-induced diabetes for up to 200 days after implantation, according to a recent article in Science Translational Medicine. To do so, they used a nanofiber-integrated cell encapsulation (NICE) device […]
UC Riverside researchers tout piezoelectric polymer for drug delivery
Researchers at the University of California, Riverside, are touting a polymer-based membrane as a potential drug delivery platform. The researchers developed the membrane made from threads of a polymer commonly used in vascular sutures, according to the university’s website. The membrane can be loaded with therapeutic drugs and implanted in the body before mechanical forces […]
UroGen Pharma raises $75M
UroGen Pharma (NSDQ:URGN) announced today that it entered into a funding agreement with RTW Investments worth $75 million. Princeton, N.J.-based UroGen’s agreement with RTW will see the biopharmaceutical company receive $75 million in upfront cash in return for tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto (mitomycin) for pyelocalyceal […]
